GPC3 and hepatocellular carcinoma: The limited effectiveness of the systemically delivered anti‐GPC3 CAR‐T cells in these clinical trials prompted us to explore the potential of exploiting the liver‐specific vessel system for locoregional CAR‐T cell delivery for HCC treatment.